Related Experiment Video
Updated: May 16, 2026
08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
[An update on the treatment options for multiple sclerosis].
1Department of Clinical Research, Hokkaido Medical Center, Sapporo, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|December 5, 2012
Summary
Multiple sclerosis (MS) treatments have advanced significantly, with new disease-modifying therapies (DMTs) offering more options. Ongoing research promises even more effective therapeutic strategies for MS patients.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Context:
- Multiple sclerosis (MS) treatment landscape is rapidly evolving.
- Recent approvals and ongoing clinical trials are expanding therapeutic options.
- Fingolimod represents a new oral disease-modifying therapy (DMT) for relapsing-remitting MS (RRMS).
Purpose:
- To review recent advancements in MS therapeutic strategies.
- To discuss the current landscape of DMTs for RRMS.
- To highlight potential future treatments for MS.
Summary:
- The article examines progress in MS management, focusing on disease-modifying therapies (DMTs).
- It details the availability of various DMTs in Japan and Western countries for RRMS.
- Current research and upcoming drug trials indicate a promising future with diverse MS treatment options.
Impact:
- Provides an overview of current and emerging MS therapies.
- Informs clinicians and researchers about the expanding treatment armamentarium for MS.
- Highlights the positive outlook for managing MS with novel therapeutic strategies.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...